References
1. Attali-Soussay K, Jegou JP, Clerc B. Retrobulbar tumors in dogs and cats: 25 cases. Vet Ophthalmol 2001;4:19-27.
2. Gelatt KN. Veterinary ophthalmology, 6th ed: Wiley Blackwell, 2021:Diseases and surgery of the canine orbit, 879-922.
3. Isaza D, Robinson NA, Pizzirani S, Pumphrey SA. Evaluation of cytology and histopathology for the diagnosis of feline orbital neoplasia: 81 cases (2004-2019) and review of the literature. Vet Ophthalmol 2020;23:682-689.
4. Bell CM, Schwarz T, Dubielzig RR. Diagnostic features of feline restrictive orbital myofibroblastic sarcoma. Vet Pathol 2011;48:742-50.
5. Billson FM, Miller-Michau T, Mould JR, Davidson MG. Idiopathic sclerosing orbital pseudotumor in seven cats. Vet Ophthalmol 2006;9:45-51.
6. Diehl KA, Pryor SG, Teixeira LBC. Orbital invasive squamous cell carcinoma with adnexal involvement clinically mimicking feline restrictive orbital myofibroblastic sarcoma: 19 cases (1990-2016). Vet Ophthalmol 2018;21:281-289.
7. Thomasy SM, Cissell DD, Arzi B, et al. Restrictive orbital myofibroblastic sarcoma in a cat–cross-sectional imaging (MRI & CT) appearance, treatment, and outcome. Vet Ophthalmol 2013;16 Suppl 1:123-9.
8. Miller SA, van der Woerdt A, Bartick TE. Retrobulbar pseudotumor of the orbit in a cat. J Am Vet Med Assoc 2000;216:356-8, 345.
9. Maggs DJ, Miller PE, Ofri R, Slatter D. Slatter’s fundamentals of veterinary ophthalmology, 6th ed: Elsevier, 2018:Diseases of the orbit, 101-126.
10. Withrow SJ, Vail DM, Page RL. Withrow & MacEwen’s small animal clinical oncology, 5th ed: Elsevier/Saunders, 2013:xvi, 750 p.
11. Londhe P, Gutwillig M, London C. Targeted Therapies in Veterinary Oncology. Vet Clin North Am Small Anim Pract 2019;49:917-931.
12. Thamm DH, Weishaar KM, Charles JB, Ehrhart EJ, 3rd. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. Vet Comp Oncol 2020;18:169-175.
13. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-65.
14. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia((R))) in solid tumours. Vet Comp Oncol 2012;10:194-205.
15. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-68.
16. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-34.
17. Berger EP, Johannes CM, Post GS, et al. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. J Feline Med Surg 2018;20:95-102.
18. Hasegawa Y, Shosu K, Tsuji K, et al. Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation. Scientific Reports 2022;12.
19. Azevedo C, Brawner W, Schleis Lindley S, Smith A. Multimodal non-surgical treatment of a feline tracheal adenocarcinoma. Journal of Feline Medicine and Surgery Open Reports 2017;3:205511691668963.
20. Todd JE, Nguyen SM. Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate. Journal of Feline Medicine and Surgery Open Reports 2020;6:205511692092491.
21. McGregor O, Moore AS, Yeomans S. Management of a feline gastric stromal cell tumour with toceranib phosphate: a case study. Aust Vet J 2020;98:181-184.
22. Dedeaux AM, Langohr IM, Boudreaux BB. Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate. Can Vet J 2018;59:751-754.
23. Petrucci G, Henriques J, Gregorio H, et al. Metastatic feline mammary cancer: prognostic factors, outcome and comparison of different treatment modalities - a retrospective multicentre study. J Feline Med Surg 2021;23:549-556.
24. Olmsted GA, Farrelly J, Post GS, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013. J Feline Med Surg 2017;19:568-575.
25. Wiles V, Hohenhaus A, Lamb K, Zaidi B, Camps-Palau M, Leibman N. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma. J Feline Med Surg 2017;19:185-193.
26. Kopke MA, Gal A, Piripi SA, Poirier VJ. Squamous cell carcinoma of the anal sac in two cats. J Small Anim Pract 2021;62:704-708.
27. Holtermann N, Kiupel M, Hirschberger J. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. Vet Comp Oncol 2017;15:632-640.
28. Gelatt KN. Veterinary ophthalmology, 6th ed: Wiley Blackwell, 2021:Feline ophthalmology, 1665-1840.
29. Gilger BC, McLaughlin SA, Whitley RD, Wright JC. Orbital neoplasms in cats: 21 cases (1974-1990). J Am Vet Med Assoc 1992;201:1083-6.
30. Rossi F, Marconato L, Sabattini S, et al. Comparison of definitive-intent finely fractionated and palliative-intent coarsely fractionated radiotherapy as adjuvant treatment of feline microscopic injection-site sarcoma. J Feline Med Surg 2019;21:65-72.
31. Poirier VJ, Thamm DH, Kurzman ID, et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 2002;16:726-31.
32. Saba CF, Vail DM, Thamm DH. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. Vet Comp Oncol 2012;10:283-91.
33. Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004;54:25-33.
34. Harper A, Blackwood L. Toxicity and response in cats with neoplasia treated with toceranib phosphate. J Feline Med Surg 2017;19:619-623.
35. Merrick CH, Pierro J, Schleis SE, et al. Retrospective evaluation of toceranib phosphate (Palladia(R)) toxicity in cats. Vet Comp Oncol 2017;15:710-717.